Form 4: Dyne Therapeutics SVP Richard Scalzo Reports Stock Sales to Cover Tax Obligations

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• On May 16, 2024, Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 2,126 shares of common stock at a weighted average price of $28.2.
• He also sold 462 shares at a weighted average price of $28.59.
• These sales were to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan entered into on January 25, 2024.
• Following these transactions, Scalzo beneficially owns 116,695 shares, including 110,016 unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales for tax purposes. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were not based on current insider information.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.

Stakeholder Impact

• The stock sales may have a minor dilutive effect on existing shareholders.

Key Dates